Mendelspod Podcast

5:31

Gene and Tonic: Competition for 23andMe, Four Tips...

Mendelspod Podcast ·

2015/04/10

An Old New DTC Co. on the MoveLet’s start with a bit of trivia. What company has resorted to selling genetic ancestry testing online direct to consumers? Hint: the company is located in the San Francisco Bay area, has banked more than 800,000 samples from customers all over the world, and is slowly transforming itself into major biomedical player.That’s right. You got it. It’s Ancestry.com. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus

en

24:19

Improving the Backbone of Clinical Genomics : Valerie...

Mendelspod Podcast ·

2015/04/07

When President Bill Clinton stood with Francis Collins and Craig Venter in 2001 to announce the sequencing of the genome, the genome wasn’t really done. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

5:06

Gene and Tonic: The ACA Turns Five, Ten Reasons to...

Mendelspod Podcast ·

2015/04/03

Actually there was no news this week. It turns out the whole industry took the week off to watch the stunning Ken Burns documentary on cancer. No, that’s not true. We did find some news. How about this? The Affordable Care Act turned five this past week. Happy Birthday, ObamaCare! So we thought we’d share some important numbers about the ACA:11.7 million: the number of Americans who have signed up for 2015 coverage.46%: the increase in enrollment from 2014 to 2015. This is a public

en

22:56

Behind the Sequencing Bench with Dale Yuzuki

Mendelspod Podcast ·

2015/03/31

Will tech companies like Google and Apple be good at life science applications? We pursue this question today with Dale Yuzuki, the avid life science blogger, scientist, and now a marketing manager at Thermo Fisher. (See his recent blog, The Core Competency of Google Is Not Life Sciences.) This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

5:48

Gene and Tonic: The Tenth Commandment of Science,...

Mendelspod Podcast ·

2015/03/27

We were off last week, so there’s plenty to talk about. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

21:25

It’s Pretty Bad: Andy Brooks of RUCDR on Sample Quality

Mendelspod Podcast ·

2015/03/19

The future of diagnostics is in the hands of those taking care of the biospecimen samples says, Andy Brooks our final guest in the series, Improving Biospecimen Standards. Andy is the Chief Operating Officer at Rutgers University Cell and DNA Repository, or RUCDR. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

21:40

Knowing More about What We Don’t Know: John McPherson...

Mendelspod Podcast ·

2015/03/17

More than with any other major disease, the understanding and treatment of cancer is being transformed by genomics. And these are early days.John McPherson has been involved in sequencing since the original Human Genome Project. He now directs the Genome Technologies Program at the Ontario Institute for Cancer Research. John chaired a panel on cancer genomics at the recent AGBT, or Advances in Genome Biology and Technology conference, and shares his thoughts on this year's meeting. This is a

en

4:19

Gene and Tonic: The iWatch and Research Kit, 23andMe...

Mendelspod Podcast ·

2015/03/13

Friday March 13thIt’s Friday already and time for Gene and Tonic, our wrap of the week’s headlines.On Monday, Apple’s CEO, Tim Cook, announced that the iWatch is indeed a reality. The iWatch has all the wearable techies and mobile health folks doing somersaults. But it was what happened afterward that was so interesting. Did you hear about this? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

16:02

In Partnership with IBM’s Watson, Pathway Genomics...

Mendelspod Podcast ·

2015/03/12

Direct-to-consumer (DTC) genetic testing has had a bumpy ride.Back in 2010, Pathway Genomics and Walgreens made a deal to sell DTC genetic tests in thousands of Walgreens drugstores. Within 48 hours of the deal being announced, it collapsed. The FDA sent a letter to Pathway basically asking them what the hell they were doing. Walgreens quickly elected to put the kibosh on the partnership. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus

en

22:40

Affymetrix CEO, Frank Witney, on Arrays in the Age of...

Mendelspod Podcast ·

2015/03/10

Go about anywhere in the life science industry, and you’ll run into someone who once worked at Affymetrix. Since the founding of Affymetrix and the development of what’s come to be known simply as the Affy chip, the company’s history has been intertwined with that of biotech and the genomics revolution. But what has become of the company today? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

5:14

Gene & Tonic: Disruption in Sequencing, Scientist...

Mendelspod Podcast ·

2015/03/06

Join Theral for a quick wrap-up of the week's biotech news:The biggest news this week has been the flow of stories coming from last week’s AGBT conference held in Florida. This is the annual all out party for the all out darling of our industry, the sequencing space. Like a debutante ball, it’s where anybody who’s anybody comes out and does their curtsy to society. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

12:59

Changing the World with Color Changing Flowers

Mendelspod Podcast ·

2015/03/05

Keira Havens is the co-founder of Revolution Bioengineering, and this week the company launched a crowd funding campaign (see video below) to produce flowers that can change colors.And what is the revolution?“We want to change the world,” says Keira. “We really want to make a difference in the way people think about biotechnology. For a long time it’s been the realm of large companies and behind-the-scenes labs, and we want to make it a part of folks' everyday lives.” This is a public episode. If

en

25:04

Cancer Researcher at Mayo Says Illumina Platform...

Mendelspod Podcast ·

2015/03/03

Today we bring you a story which you probably wouldn’t have heard at last week’s AGBT conference at Marcos Island. While PacBio and 10X Genomics were getting most of the buzz at the annual show on all things sequencing, it could be the new BGI/Complete Genomics platform that steals the show later this year, says David Smith, a cancer researcher at the Mayo Clinic.In his research, David uses sequencing to analyze the connection between the human papillomavirus (HPV) with oropharyngeall cancer. This

en

25:19

Returning to Old Biotech Model, OncoMed Boasts of...

Mendelspod Podcast ·

2015/02/24

For many years, the trend in biotech was for drug development companies to pursue one or maybe two drug candidates, or assets, as they’re called in industry parlance. Go lean and attract the attention of big pharma or investors in the late stage trials. But today’s guest says there is more innovation when the biotech organization invests in a technology platform that produces multiple drug candidates. Paul Hastings is the CEO of OncoMed, a company developing drugs that target cancer stem cells.

en

28:11

Cutting through the Hype in Healthcare Innovation...

Mendelspod Podcast ·

2015/02/20

In today’s special studio interview, the health tech duo, David Shaywitz and Lisa Suennen, walk us through the changing paradigms around healthcare. They offer their thoughts on some of the new digital health and peer-to-peer social platforms which are becoming integrated in daily clinical care. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

16:24

A Call to Consumers to Lead the Shift in Healthcare:...

Mendelspod Podcast ·

2015/02/17

One of those attending the recent White House gathering where Obama announced the Precision Medicine Initiative was a woman who has worked tirelessly as a patient advocate for over twenty years. She’s an award winning scientist and the CEO of the Genetic Alliance: Sharon Terry joins us to kick off a new series, Personalized Medicine and the Consumerization of Healthcare. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

15:56

In Autoimmune Disease, Finding Clarity Beyond the...

Mendelspod Podcast ·

2015/02/13

Today we bring you a story which fits nicely in the vein of personalized medicine. But this time with a twist.We talk with the CEO of Protagen, a company that has developed a platform to find new biomarkers for disease, particularly autoimmune diseases such as SLE, or Systemic Lupus Erythematosus. But the platform is based on the hunt for genetic mutations. Rather the company is using antibodies, or proteins to better define disease and disease populations. The company is able to stratify

en

28:24

Myriad Settlements Mark End of an Era: Antoinette...

Mendelspod Podcast ·

2015/02/10

This past month one of the most successful genetic testing companies, Myriad Genetics, has been settling one gene patent case after another. Also, the FDA has been attempting to regulate some very complicated lab testing. So we figured we better talk to a lawyer about the devil in the details. We’ve chosen Antoinette Konski of the law firm, Foley and Lardner.Antoinette agrees that the Myriad settlements indicate the end of an era with gene patents. So how is she advising her life science clients

en

29:50

David Schwartz on the Future of Sequencing

Mendelspod Podcast ·

2015/02/06

David Schwartz was focused on long read sequencing and the structural variations of the genome—the big picture—long before the current trend. His lab at the University of Wisconsin at Madison developed optical mapping and posted the first optical map of the human genome several years ago. And last year, they published the first optical map of a cancer genome. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

18:00

Not a Stenographer to Power: Luke Timmerman and the...

Mendelspod Podcast ·

2015/02/03

Just less than a year ago, the national biotech editor at Xconomy, Luke Timmerman, left his post. Yeah, he just left it. Gone was the regular Monday column that helped us all absorb the newest trends in biotech. Gone were the lists of companies to watch out for that made sense even if we weren't up to date on Luke's sports analogies. One day the columns were here, then they were gone. Luke said he was busy with a biography of Lee Hood, the guy who brought us automated DNA sequencing. But we

en

All Episodes

Similar Podcasts

天方烨谈

基因频道

Mendelspod Podcast

Theral Timpson

DMCN Journal

John Wiley & Sons Ltd

汪诘：科学有故事（主打）

科学有故事

Homesteading and Permaculture by Paul Wheaton

paul wheaton